DERM supply chain intelligence for Journey Medical Corporation: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Journey Medical Corporation (DERM) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| FBIO | Fortress Biotech, Inc. | 90% | Reciprocal relationship from FBIO graph: The Amendment amended the financial covenant requiring that product net sales of Journey Medical Corporation, a controlled subsidiary of the Company, meet a c… |
| FBIOP | FBIOP | 72% | Reciprocal relationship from FBIOP graph: Reciprocal relationship from DERM graph: Reciprocal relationship from FBIOP graph: Reciprocal relationship from DERM graph: Reciprocal relationship from FBIO… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from DERM graph: t of assets, we currently, and will continue to, secure manufacturing agreements with either a counterparty to a tra… |
| ORANY | ORANY | 72% | t of assets, we currently, and will continue to, secure manufacturing agreements with either a counterparty to a transaction, with one or more of our contract manufacturers or additional contract man… |
| RDY | Dr. Reddy's Laboratories Limited | 72% | Reciprocal relationship from RDY graph: Reciprocal relationship from DERM graph: Reciprocal relationship from RDY graph: me 5,217 5,426 5,655 License fees (2) 4,503 3,789 2,113 Rs. 335,933 Rs. 325,53… |
| VYNE | VYNE Therapeutics Inc. | 72% | Reciprocal relationship from VYNE graph: Reciprocal relationship from DERM graph: Reciprocal relationship from VYNE graph: Reciprocal relationship from DERM graph: er serious labor problems that have… |
| VYNE | VYNE Therapeutics Inc. | 72% | er serious labor problems that have materially impeded our business operations. Our human capital management objectives include, as applicable, identifying, recruiting, retaining, incentivizing, and … |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CUTIA | CUTIA | 92% | Other revenue for the three-month period ended March 31, 2026 reflects sales-based royalties earned on the net sales of Amzeeq by Cutia. |
| FBIO | Fortress Biotech, Inc. | 72% | NOTE 1. ORGANIZATION AND PLAN OF BUSINESS OPERATIONS Journey Medical Corporation (“Journey” or the “Company”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and ma… |
| FBIO | Fortress Biotech, Inc. | 72% | Reciprocal relationship from FBIO graph: Reciprocal relationship from DERM graph: NOTE 1. ORGANIZATION AND PLAN OF BUSINESS OPERATIONS Journey Medical Corporation (“Journey” or the “Company”) is a co… |
| FBIOP | FBIOP | 72% | Reciprocal relationship from FBIOP graph: racting with third parties for manufacturing, testing, warehousing, distribution, cash collection and related commercial activities; ● we are required by the… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from DERM graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from DERM graph: t of assets, we currently, and wi… |
| ORANY | ORANY | 72% | t of assets, we currently, and will continue to, secure manufacturing agreements with either a counterparty to a transaction, with one or more of our contract manufacturers or additional contract man… |
| RDY | Dr. Reddy's Laboratories Limited | 72% | Reciprocal relationship from RDY graph: ell lung cancer following the results of the futility analysis. As a result, the Company recorded an impairment loss of Rs. 914 (U.S.$ 10 ) in the consolidated… |
| VYNE | VYNE Therapeutics Inc. | 72% | er serious labor problems that have materially impeded our business operations. Our human capital management objectives include, as applicable, identifying, recruiting, retaining, incentivizing, and … |
| VYNE | VYNE Therapeutics Inc. | 72% | Reciprocal relationship from VYNE graph: Reciprocal relationship from DERM graph: er serious labor problems that have materially impeded our business operations. Our human capital management objectiv… |
| B-RILEY-SECURITIES-INC | B-RILEY-SECURITIES-INC | 62% | 6%, to $1.1 million for the three-month period ended March 31, 2026, from $1.1 million for the three-month period ended March 31, 2025, driven by the start of amortization on the anti-itch acquired i… |
| LAKE-STREET-CAPITAL-MARKETS-LLC | LAKE-STREET-CAPITAL-MARKETS-LLC | 62% | 6%, to $1.1 million for the three-month period ended March 31, 2026, from $1.1 million for the three-month period ended March 31, 2025, driven by the start of amortization on the anti-itch acquired i… |
| SWK-FUNDING-LLC | SWK-FUNDING-LLC | 62% | NOTE 1. ORGANIZATION AND PLAN OF BUSINESS OPERATIONS Journey Medical Corporation (“Journey” or the “Company”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and ma… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| DERM-DEBT | Debt stack $25.5M | 90% | Market cache reports total debt of $25.5M. |
| DERM-DEBT-9053 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2021-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| DERM-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 71 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| RDY | Dr. Reddy's Laboratories Limited | 100.00 | 1 | ['customer', 'supplier'] |
| VYNE | VYNE Therapeutics Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| OCSL | Oaktree Specialty Lending Corporation | 100.00 | 2 | |
| TGTX | TG Therapeutics, Inc. | 100.00 | 2 | |
| ORANY | ORANGE | 100.00 | 1 | ['customer', 'supplier'] |
| FBIOP | Fortress Biotech, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| FBIO | Fortress Biotech, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| MBIO | Mustang Bio, Inc. | 100.00 | 2 | |
| CUTIA | CUTIA | 63.48 | 1 | ['receiving'] |
| BFRGW | BullFrog AI Holdings, Inc. | 50.00 | 2 | |
| AYTU | Aytu BioPharma, Inc. | 50.00 | 2 | |
| ARQQW | Arqit Quantum Inc. | 50.00 | 2 | |
| CYCN | Cyclerion Therapeutics, Inc. | 50.00 | 2 | |
| CMCM | Cheetah Mobile Inc. | 50.00 | 2 | |
| ASBPW | Aspire Biopharma Holdings, Inc. | 50.00 | 2 | |
| BCDRF | Banco Santander, S.A. | 50.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 50.00 | 2 | |
| EPDU | ENTERPRISE PRODUCTS PARTNERS L.P. | 50.00 | 2 | |
| AMZE | Amaze Holdings, Inc. | 50.00 | 2 | |
| BLTE | Belite Bio, Inc | 50.00 | 2 |